Clinical trials · California
Metastatic Cancer clinical trials in California
We’re tracking 373 recruiting metastatic cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07775287RecruitingPhase 3
Petosemtamab plus chemotherapy for advanced colorectal cancer
This study tests a new drug called petosemtamab combined with chemotherapy for people with advanced colorectal cancer that has not responded to one prior treatment. The trial aims to see if adding petosemtamab helps the cancer shrink or grow more slowly compared to adding a standard targeted therapy like cetuximab or bevacizumab.
Los Angeles, CaliforniaAges 18 years+ - NCT05398302RecruitingPhase 1
Biopsies during prostate cancer treatment to study resistance
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Los Angeles, CaliforniaAges Any age - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Duarte, CaliforniaAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Orange, CaliforniaAges 18 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
San Francisco, CaliforniaAges 18 years+ - NCT04329494RecruitingPhase 1
Study of targeted drug delivery into the abdomen using PIPAC
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Duarte, CaliforniaAges 18 years+ - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
Sylmar, CaliforniaAges 18 years+ - NCT06102902RecruitingPhase 1
New drug added to chemotherapy for BRAF-mutated colorectal cancer
This trial combines a new drug called ZEN003694 with two standard chemotherapy drugs (cetuximab and encorafenib) to see if it can help people with a specific type of colorectal cancer that has the BRAF V600E mutation. This mutation makes the cancer grow, and the new drug targets it, potentially making the treatment more effective.
Costa Mesa, CaliforniaAges 18 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Study of datopotamab deruxtecan with chemo for advanced bladder cancer
This trial is testing a new drug combination for advanced bladder cancer that has grown despite previous treatment. It pairs a targeted therapy (datopotamab deruxtecan) with chemotherapy, and the goal is to see if it can slow down or stop the cancer better than standard chemo alone.
Orange, CaliforniaAges 18 years+ - NCT06996782RecruitingPhase 1/Phase 2
Lung cancer study testing new combination treatments
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Santa Rosa, CaliforniaAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Duarte, CaliforniaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Berkeley, CaliforniaAges 18 years+ - NCT07128680RecruitingPhase 1
Immunotherapy with or without a gut bacteria pill for kidney cancer
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
Irvine, CaliforniaAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Newport Beach, CaliforniaAges 18 years+ - NCT06224673RecruitingPhase 2
Testing ARX788 for HER2-low advanced breast cancer
This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT04205968RecruitingPhase 2
Testing ramucirumab with chemo for advanced small bowel cancer
This trial studies whether adding ramucirumab to chemotherapy (either paclitaxel or FOLFIRI) works better for advanced small bowel adenocarcinoma that has already been treated with certain prior medicines. It may help shrink tumors or slow cancer growth in people whose cancer has progressed.
San Diego, CaliforniaAges 18 years+ - NCT07594431RecruitingPhase 2
New radiation therapy for cancer that has spread to the body
This study tests a newer radiation technique called LATTICE radiotherapy compared to standard radiation for treating cancer tumors that have spread to other parts of the body. The goal is to see if the new approach works better and causes fewer side effects.
Palo Alto, CaliforniaAges 12 years+ - NCT07550088RecruitingPhase 2
Combination therapy for colorectal cancer with liver tumors
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
La Jolla, CaliforniaAges 18 years+ - NCT07406633RecruitingPhase 2
KQB198 plus imatinib for advanced GIST
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT06859801Recruiting
Bone pain study combining ablation and radiation
This study looks at combining two treatments for painful bone tumors that have spread from other cancers. It tests if using both treatments together provides better pain relief than either alone.
San Diego, CaliforniaAges 21 years+ - NCT06682390Recruiting
Race and diet study for men on hormone therapy
This study explores how race affects nutrition for men receiving hormone therapy (ADT) for prostate cancer. It may help researchers understand if different dietary approaches are needed based on race.
Los Angeles, CaliforniaAges 18 years+
Metastatic Cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting metastatic cancer studies listed above.
- City of Hope · 4 studies
- University of California, San Francisco · 3 studies
- Research Site · 2 studies
- UC San Diego Health · 2 studies
- USC Norris Comprehensive Cancer Center · 2 studies
- Alta Bates Summit Medical Center-Herrick Campus
- Buhler Specialty Pavilion
- City of Hope - National Medical Center
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Cancer trials in other states
Common questions
- Are there metastatic cancer clinical trials in California?
- Yes. We're currently tracking 373 recruiting metastatic cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.